This article is more than 5 years old. Information may no longer be current.

Miraca adds Simponi to therapeutic drug monitoring platform for IBD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Miraca Life Sciences announced it has expanded its InformTx therapeutic drug monitoring platform to include the first assay for Simponi in the U.S.

“Monitoring of therapeutic drug levels and anti-drug antibodies is extremely important for the effective management of inflammatory bowel disease,” Richard Lash, MD, chief medical officer and executive vice president of operations for Miraca Life Sciences, said in a press release. “With our InformTx offering now encompassing six drugs, Miraca Life Sciences can serve even more gastroenterologists and their patients.”

In addition to assays for Simponi (golimumab, Janssen), InformTx is also the only therapeutic drug monitoring service available in the U.S. for Cimzia (certolizumab pegol, UCB) and Stelara (ustekinumab, Janssen), and it also provides assays for Remicade (infliximab, Janssen), Humira (adalimumab, AbbVie) and Entyvio (vedolizumab, Takeda).

InformTx uses ELISA technology, and after a 5-day turnaround, the report provides quantitative results, historical result data and guidance from current peer-reviewed medical literature, according to the press release.

Disclosures: Lash is employed by Miraca Life Sciences.